	US 11,878,048 B2
	Use of the extracellular domain of transferrin receptor 2 for the diagnosis and treatment of primary or secondary sclerosing diseases
Martina Rauner, Dresden (DE); Lorenz C. Hofbauer, Dresden (DE); Uwe Platzbecker, Dresden (DE); and Ulrike Baschant, Dresden (DE)
Assigned to Kymab Limited, Cambridge (GB)
Appl. No. 16/622,616
Filed by Kymab Limited, Cambridge (GB)
PCT Filed Jun. 14, 2018, PCT No. PCT/EP2018/065846 § 371(c)(1), (2) Date Dec. 13, 2019, PCT Pub. No. WO2018/229210, PCT Pub. Date Dec. 20, 2018.
Claims priority of application No. 17176043 (EP), filed on Jun. 14, 2017.
Prior Publication US 2020/0215154 A1, Jul. 9, 2020
Int. Cl. A61K 38/17 (2006.01); C07K 14/705 (2006.01); G01N 33/68 (2006.01)

CPC A61K 38/177 (2013.01) [G01N 33/6893 (2013.01)]

5 Claims

1. A method of treating a primary or secondary sclerosing disease in a subject, comprising administering to the subject a protein comprising the amino acid sequence of SEQ ID NO: 1, wherein the primary or secondary sclerosing disease is associated with increased Bone Morphogenetic Protein (BMP) receptor activation by at least one ligand selected from the group consisting of BMP2, BMP4, BMP6, and BMP7.